Monday, January 21, 2013
Three companies with Phase II
data for amyotrophic lateral sclerosis believe they have identified at least
two ways to improve the odds of clinical success, even though the disease has
poorly understood biology, heterogeneous presentation and progression, and no
markers of progression or treatment response.
The first is to develop
compounds with known mechanisms of action that target features of the disease
found in all ALS patients. The second is to employ a range of strategies to
identify and augment signals of effectiveness in Phase II trials.